Globus Medical, Inc. (GMED)

Market Cap	10.62B +35.7%
Revenue (ttm)	3.10B +23.5%
Net Income	586.71M +216.2%
EPS	4.29 +221.1%
Shares Out	135.74M
PE Ratio	18.24
Forward PE	16.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,766,191
Open	78.99
Previous Close	79.78
Day's Range	77.90 - 79.95
52-Week Range	51.79 - 101.40
Beta	1.00
Analysts	Buy
Price Target	111.08 (+41.96%)
Earnings Date	May 7, 2026

About GMED

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractu...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Aug 3, 2012
• Employees: 6,000
• Stock Exchange: NYSE
• Ticker Symbol: GMED
• Website: https://www.globusmedical.com

Financial Performance

In 2025, Globus Medical's revenue was $2.94 billion, an increase of 16.65% compared to the previous year's $2.52 billion. Earnings were $537.87 million, an increase of 422.28%.

Analyst Summary

According to 14 analysts, the average rating for GMED stock is "Buy." The 12-month stock price target is $111.08, which is an increase of 41.96% from the latest price.

Price Target

$111.08

(41.96% upside)

Analyst Consensus: Buy